Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Research & Studies
Share your love
Peters Anomaly: Causes, Symptoms and Management
What Is Peters Anomaly? Peters anomaly is a rare congenital ocular condition primarily affecting the anterior segment of the eye. At its core, it’s characterized by the abnormal development of the cornea’s central layers and potential adhesions between the cornea…
Corneal Staining: Causes, Symptoms and Management
Corneal staining is a critical concept in the field of eye health, referring to a condition where the cornea, the clear front surface of the eye, becomes stained or discolored. This phenomenon is particularly significant because it often indicates underlying…
Glaucoma Market to Grow to $3.5 Billion by 2030
According to GlobalData, the glaucoma market across the seven major markets* is predicted to grow steadily from $2.8 billion in 2020 to $3.5 billion in 2030, with a compound annual growth rate (CAGR) of 2%. According to the latest analysis…
What Is Capsulorhexis and How It’s Done
What Is Capsulorhexis? Capsulorhexis, derived from the Latin “capsula” (little container) and Greek “rhexis” (rupture), refers to the precise and controlled tear of the anterior lens capsule during cataract surgery. This procedure creates a circular opening through which the cloudy…
All About Phacoemulsification Procedure | OBN
The phacoemulsification procedure has transformed cataract surgery, offering a less invasive and more efficient method for cataract removal. This advanced surgical technique uses ultrasonic vibrations to emulsify the cloudy lens, which is then aspirated out and replaced with an artificial…
Alcon and Ivantis Lose Patent Battle to Sight Sciences.
Sight Sciences announced its success in defeating all four patent invalidity challenges that were filed against it by Alcon and Ivantis in the United States Patent and Trademark Office. Patent Infringement Litigation Over Hydrus® Microstent In September 2021, Sight Sciences…
Brim Biotech’s Clinical Trial for DED Kicks Off
BRIM Biotechnology has initiated the Phase 3 clinical trial of BRM421 for the treatment of Dry Eye Disease (DED) and enrolled the first patient in the trial. This multicenter, double-blind, randomized, vehicle-controlled trial will enroll over 700 patients with moderate…
The Biggest Challenges in Ophthalmology Today
A recent survey conducted by OBN on LinkedIn asked participants to identify the most pressing challenge facing the ophthalmology field today. The poll revealed that nearly half of the respondents believe patient access to care is the primary issue, followed…
New Consensus: Myopia Should Be Classified as a Disease
A new consensus report from the National Academies of Sciences, Engineering, and Medicine urges that myopia be classified as a disease requiring medical diagnosis. The report emphasizes the growing prevalence of myopia globally, which is projected to affect 5 billion…
Mount Sinai Receives $5 Million Gift for the Center for Ophthalmic Artificial Intelligence and Human Health – Mount Sinai
Mount Sinai Receives $5 Million Gift for the Center for Ophthalmic Artificial Intelligence and Human Health Mount Sinai Source: Author: | Date: 2024-10-16 07:00:00 Source: Author: | Date: 2024-10-16 07:00:00